KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Net Margin (2018 - 2025)

Historic Net Margin for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to 42.95%.

  • Aurinia Pharmaceuticals' Net Margin rose 218300.0% to 42.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.3%, marking a year-over-year increase of 395900.0%. This contributed to the annual value of 2.44% for FY2024, which is 469300.0% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Net Margin stood at 42.95% for Q3 2025, which was up 218300.0% from 30.73% recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Net Margin registered a high of 42.95% during Q3 2025, and its lowest value of 5511.93% during Q1 2021.
  • In the last 5 years, Aurinia Pharmaceuticals' Net Margin had a median value of 27.7% in 2023 and averaged 378.34%.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Net Margin crashed by 2000000000bps in 2021, and later surged by 53379100bps in 2022.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Net Margin stood at 142.38% in 2021, then skyrocketed by 36bps to 91.6% in 2022, then skyrocketed by 35bps to 59.69% in 2023, then soared by 104bps to 2.46% in 2024, then skyrocketed by 1645bps to 42.95% in 2025.
  • Its Net Margin was 42.95% in Q3 2025, compared to 30.73% in Q2 2025 and 37.37% in Q1 2025.